MDM4 is a rational target for treating breast cancers with mutant p53

Miranda, PJ; Buckley, D; Raghu, D; Pang, JB; Takano, EA; Vijayakumaran, R; Teunisse, AF; Posner, A; Procter, T; Herold, MJ; Gamell, C; Marine, JC; Fox, SB; Jochemsen, A; Haupt, S; Haupt, Y

Author(s): Miranda, PJ; Buckley, D; Raghu, D; Pang, JB; Takano, EA; Vijayakumaran, R; Teunisse, AF; Posner, A; Procter, T; Herold, MJ; Gamell, C; Marine, JC; Fox, SB; Jochemsen, A; Haupt, S; Haupt, Y;
Details: Publication Year 2017-04,Volume 241,Issue #5,Page 661-670
Journal Title: J Pathol
Publication Type: Journal Article
Abstract: Mutation of the key tumour suppressor p53 defines a transition in the progression towards aggressive and metastatic breast cancer (BC) with the poorest outcome. Specifically, the p53 mutation frequency exceeds 50% in triple-negative BC. Key regulators of mutant p53 that facilitate its oncogenic functions are potential therapeutic targets. We report here that the MDM4 protein is frequently abundant in the context of mutant p53 in basal-like BC samples. Importantly, we show that MDM4 plays a critical role in the proliferation of these BC cells. We demonstrate that conditional knockdown (KD) of MDM4 provokes growth inhibition across a range of BC subtypes with mutant p53, including luminal, Her2+ and triple-negative BCs. In vivo, MDM4 was shown to be crucial for the establishment and progression of tumours. This growth inhibition was mediated, at least in part, by the cell cycle inhibitor p27. Depletion of p27 together with MDM4 KD led to recovery of the proliferative capacity of cells that were growth-inhibited by MDM4 KD alone. Consistently, we identified low levels of p27 expression in basal-like tumours corresponding to high levels of MDM4 and p53. This predicts a signature for a subset of tumours that may be amenable to therapies targeted towards MDM4 and mutant p53. The therapeutic potential of MDM4 as a target in BC with mutant p53 was shown in vitro by use of a small-molecule inhibitor. Overall, our study supports MDM4 as a novel therapeutic target for BC expressing mutant p53. Copyright (c) 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Publisher: Wiley
Research Division(s): Molecular Genetics Of Cancer
PubMed ID: 28097652
Publisher's Version: https://doi.org/10.1002/path.4877
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2017-04-12 10:42:17

Last Modified: 2017-04-12 11:25:11